Glucocorticoids synergize with IL-1β to induce TLR2 expression via MAP Kinase Phosphatase-1-dependent dual Inhibition of MAPK JNK and p38 in epithelial cells by Sakai, Akihiro et al.
BioMed  Central
Page 1 of 16
(page number not for citation purposes)
BMC Molecular Biology
Open Access Research article
Glucocorticoids synergize with IL-1β to induce TLR2 expression via 
MAP Kinase Phosphatase-1-dependent dual Inhibition of MAPK 
JNK and p38 in epithelial cells
Akihiro Sakai1, Jiahuai Han2, Andrew CB Cato3, Shizuo Akira4 and Jian-
Dong Li*1
Address: 1Gonda Department of Cell and Molecular Biology, House Ear Institute, and the Department of Otolaryngology, University of Southern 
California, Los Angeles, CA 90057, USA, 2Department of Immunology, the Scripps Research Institute, La Jolla, CA 92037, USA, 
3Forschungszentrum Karlsruhe, Institute of Toxicology & Genetics, P.O. Box 3640, D-76021 Karlsruhe, Germany and 4Department of Host 
Defense, Research Institute for Microbial Diseases, Osaka University, CREST of Japan Science and Technology Corporation, 3-1 Yamada-oka, Suita, 
Osaka 565-0871, Japan
Email: Akihiro Sakai - asakai@hei.org; Jiahuai Han - jhan@scripps.edu; Andrew CB Cato - andrew.cato@itg.fzk.de; 
Shizuo Akira - sakira@biken.osaka-u.ac.jp; Jian-Dong Li* - jdli@hei.org
* Corresponding author    
Abstract
Background: Despite the importance of glucocorticoids in suppressing immune and inflammatory
responses, their role in enhancing host immune and defense response against invading bacteria is
poorly understood. Toll-like receptor 2 (TLR2) has recently gained importance as one of the major
host defense receptors. The increased expression of TLR2 in response to bacteria-induced
cytokines has been thought to be crucial for the accelerated immune response and resensitization
of epithelial cells to invading pathogens.
Results:  We show that IL-1β, a key proinflammatory cytokine, greatly up-regulates TLR2
expression in human epithelial cells via a positive IKKβ-IκBα-dependent NF-κB pathway and
negative MEKK1-MKK4/7-JNK1/2 and MKK3/6-p38 α/β pathways. Glucocorticoids synergistically
enhance IL-1β-induced TLR2 expression via specific up-regulation of the MAP kinase phosphatase-
1 that, in turn, leads to dephosphorylation and inactivation of both MAPK JNK and p38, the negative
regulators for TLR2 induction.
Conclusion:  These results indicate that glucocorticoids not only suppress immune and
inflammatory response, but also enhance the expression of the host defense receptor, TLR2. Thus,
our studies may bring new insights into the novel role of glucocorticoids in orchestrating and
optimizing host immune and defense responses during bacterial infections and enhance our
understanding of the signaling mechanisms underlying the glucocorticoid-mediated attenuation of
MAPK.
Background
Epithelial cells are often situated at host-environment
boundaries, and thus act as the first line of defense against
bacterial pathogens [1]. The epithelial cells are not merely
a passive barrier but can detect foreign pathogens and gen-
erate a range of mediators that play important roles in the
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activation of innate and adaptive immunity. For effective
host defense, the epithelial cells recognize highly con-
served structural motifs only expressed by microbial path-
ogens, called pathogen-associated molecular patterns
(PAMPs). Toll-like receptors (TLRs) play a critical role in
early innate immunity to invading microorganisms by
sensing PAMPs [2]. Stimulation of TLRs by PAMPs initi-
ates a signaling cascade that induces the production and
secretion of proinflammatory cytokines [3]. Moreover,
stimulation of TLRs also induces the production of effec-
tor cytokines that leads to activation of adaptive
immunity.
Mammalian TLRs were originally found as homologues of
the Drosophila Toll [4]. TLRs are type I transmembrane
receptors, that possess extracellular leucine-rich repeats
domains flanked by cytoplasmic domains [4,5]. Although
at least 10 TLRs have been identified, only two TLRs, TLR2
and TLR4, have been well-studied. While TLR4 is mainly
involved in Gram-negative bacteria lipopolysaccharide
(LPS) signaling, TLR2 can respond to a variety of Gram-
positive bacterial products, including peptidoglycan, lipo-
protein, lipoteichoic acid and lipoarabinomannan. In
addition to Gram-positive bacterial PAMPs, TLR2 also rec-
ognizes factors released by Gram-negative bacteria includ-
ing nontypeable Haemophilus influenzae (NTHi) [6,7] and
coccobacilli, Neisseria meningitidis [8] as well as the Myco-
plasma lipopeptides [9,10]. The importance of TLR2 in
host defense was further demonstrated by studies of
knockout mice showing decreased survival of TLR2-defi-
cient mice after infection with Gram-positive Staphylococ-
cus aureus [11]. Thus, it is clear that TLR2 plays a crucial
role in host defense against a variety of microbial
pathogens.
In contrast to its relatively high level of expression in lym-
phoid tissues, TLR2 is expressed at low levels in epithelial
cells. A key issue that has thus been raised is whether the
low amount of TLR2 expressed in epithelial cells is suffi-
cient for mediating the host defense response against
invading microbial pathogens. Our recent studies
revealed that TLR2, although expressed at very low level in
unstimulated human epithelial cells, is greatly up-regu-
lated by NTHi via a positive IKKβ-IκBα-dependent NF-κB
pathway and a negative MKK3/6-p38α/β pathway [12].
Moreover, glucocorticoids synergistically enhance NTHi-
induced expression of TLR2 via a negative cross-talk with
p38 MAP kinase pathway, supporting the notion that glu-
cocorticoids plays an important role in orchestrating and
optimizing immune functions, including host defense,
during bacterial infections [13,14]. However, still unclear
is whether up-regulation of TLR2 expression in epithelial
cells can also be generalized to other key mediators such
as proinflammatory cytokines, e.g. interleukin 1-β (IL-1β)
and if so, whether the cytokine-mediated up-regulation of
TLR2 can also be further enhanced by glucocorticoids.
IL-1β, a proinflammatory cytokine, is produced by vari-
ous cell types including epithelial cells and can be strongly
induced during bacterial infections [15]. It has been rec-
ognized as one of the key mediators of the host response
to microbial invasion, inflammation, immunological
reactions and tissue injury [16]. Although it has been
shown to induce the expression of a variety of non-struc-
tural, function-associated genes that are expressed during
inflammation, particularly other cytokines, whether IL-1β
also regulates the expression of host defense receptor
TLR2 in human epithelial cells is still unknown. In addi-
tion, it is still unclear whether the IL-1β-mediated TLR2
expression can also be enhanced by glucocorticoids.
Here we show that IL-1β up-regulates TLR2 via a positive
IKKβ-IκBα-dependent NF-κB signaling pathway and neg-
ative MKK3/6-p38α/β and MEKK1-MKK4/7-JNK1/2 path-
ways in human epithelial cells. Surprisingly,
glucocorticoids synergistically enhance the IL-1β-induced
TLR2 expression via a MKP-1-dependent dual inhibition
of MAPK p38 and JNK signaling pathways. These studies
may provide novel insights into the role of IL-1β and glu-
cocorticoids in orchestrating and optimizing host
immune and defense responses and lead to new therapeu-
tic strategies for modulating innate immune and inflam-
matory responses for bacterial infections.
Results
IL-1β selectively up-regulates TLR2, but not TLR4, in 
human epithelial cells
We first examined whether IL-1β up-regulates TLR2
expression in human epithelial cells. Human epithelial
HeLa cells were first treated with IL-1β and the relative
quantity of TLR2 mRNA was then measured by perform-
ing real-time quantitative PCR analysis. As shown in Fig-
ure 1a and 1b, IL-1β greatly up-regulated the TLR2 mRNA,
but not TLR4 mRNA, in HeLa cells in a time- and dose-
dependent manner. Similar results were also observed in
primary human bronchial epithelial (NHBE) cells (Figure
1c). To further determine whether up-regulation of TLR2
mRNA is accompanied by elevated TLR2 protein, Western
blot analysis was performed using antibodies against
human TLR2. As shown in Figure 1d, up-regulation of
TLR2 was also observed at protein level. These data dem-
onstrate that TLR2, but not TLR4, is greatly up-regulated
by IL-1β in human epithelial cells.
Activation of NF-κB via IKKβ-IκBα signaling pathway is 
required for IL-1β-induced TLR2 up-regulation
We next sought to determine which intracellular signaling
pathways are involved in IL-1β-induced TLR2 up-regula-
tion. Based on the essential involvement of NF-κB inBMC Molecular Biology 2004, 5 http://www.biomedcentral.com/1471-2199/5/2
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IL-1β up-regulates TLR2, but not TLR4, in human epithelial cells including primary bronchial epithelial cells Figure 1
IL-1β up-regulates TLR2, but not TLR4, in human epithelial cells including primary bronchial epithelial cells. A, 
IL-1β up-regulates TLR2 mRNA, but not TLR4 mRNA, in HeLa cells in a time-dependent manner. Cells were treated with IL-
1β (10 ng/ml) for the indicated time periods. The expression of TLR2 and TLR4 at mRNA level was then measured by real-
time quantitative PCR in IL-1β-treated and -untreated human cervix epithelial HeLa cells. TLR2 and TLR4 mRNA levels were 
normalized to the level of cyclophilin that served as an internal control for the amount of RNA used in each reaction. Values 
are the mean ± SD; n = 3. The symbols (*) indicate results significantly different (p < 0.01) from unstimulated condition. B, IL-
1β up-regulates TLR2 mRNA, but not TLR4 mRNA, in HeLa cells in a dose-dependent manner. HeLa cells were treated with 
the indicated concentration of IL-1β for 3 h. Values are the mean ± SD; n = 3. The symbols (*) indicate results significantly dif-
ferent (p < 0.01) from unstimulated condition. C, IL-1β up-regulates TLR2 mRNA, but not TLR4 mRNA, in primary human 
bronchial epithelial NHBE cells. NHBE cells were treated with IL-1β (10 ng/ml) for 3 h. Values are the mean ± SD; n = 3. The 
symbols (*) indicate results significantly different (p < 0.01) from unstimulated condition. D, IL-1β also induces expression of 
TLR2 at protein level in HeLa cells. HeLa cells were treated for 5 h with IL-1β (10 ng/ml). Protein level of TLR2 was then 
assessed by Western blot analysis using an anti-hTLR2 antibody. β-Actin was used as a protein loading control.
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IKKβ-IκBα-dependent activation of NF-κB is required for IL-1β-induced TLR2 up-regulation Figure 2
IKKβ-IκBα-dependent activation of NF-κB is required for IL-1β-induced TLR2 up-regulation. A, IL-1β induces 
IκBα phosphorylation and degradation in HeLa cells as assessed by Western blot analysis. Cells were treated with IL-1β (10 ng/
ml) for the indicated time periods. B, MG 132 inhibits IL-1β-induced NF-κB nuclear translocation, IκBα degradation and TLR2 
up-regulation in HeLa cells. For Western blotting and immunofluorescent staining, cells were pretreated with MG132 (1 µM) 
for 2 h prior to treatment with IL-1β (10 ng/ml) for 20 min. For the measurement of TLR2 mRNA, cells were treated with IL-
1β (10 ng/ml) for 3 h after MG132 pretreatment. Values are the mean ± SD; n = 3. The symbols indicate results significantly dif-
ferent (p < 0.01) from unstimulated condition (*) and IL-1β-stimulated condition (without MG132)(**). C, Overexpression of a 
transdominant mutant of IκBα [IκBα [(S32A, S36A)] and a dominant-negative mutant of IKKβ [IKKβ (K44A)] inhibit IL-1β-
induced TLR2 up-regulation in HeLa cells. HeLa cells were treated with IL-1β (10 ng/ml) for 3 h. Values are the mean ± SD; n 
= 3. The symbols indicate results significantly different (p < 0.01) from unstimulated condition (*) and IL-1β-stimulated condi-
tion (without dominant-negative construct)(**). D, MG 132 also inhibits IL-1β-induced NF-κB nuclear translocation and TLR2 
up-regulation in NHBE cells. For immunofluorescent staining, cells were pretreated with MG132 (1 µM) for 2 h prior to treat-
ment with IL-1β (10 ng/ml) for 20 min. For the measurement of TLR2 mRNA, cells were treated with IL-1β (10 ng/ml) for 3 h 
after MG132 pretreatment. Values are the mean ± SD; n = 3. The symbols indicate results significantly different (p < 0.01) from 
unstimulated condition (*) and IL-1β-stimulated condition (without MG132)(**). E, Overexpression of a transdominant mutant 
of IκBα (S32A, S36A) and a dominant-negative mutant of IKKβ (K44A) reduce IL-1β-induced TLR2 up-regulation in NHBE 
cells. Cells were treated with IL-1β (10 ng/ml) for 3 h. Values are the mean ± SD; n = 3. The symbols indicate results signifi-
cantly different (p < 0.01) from unstimulated condition (*) and IL-1β-stimulated condition (without dominant-negative 
construct)(**).
CON 5 10 15 45 30 180 60 Time (min)
p-Iκ κ κ κBα α α α
Iκ κ κ κBα α α α
(A) (B)
(C)
(D)
(E)
MG132  
    +
 IL-1β β β β
CON IL-1β β β β MG132  
R
e
l
a
t
i
v
e
 
Q
u
a
n
t
i
t
y
 
o
f
 
T
L
R
2
 
m
R
N
A
 
0
2
4
6
8
-
-
+
+ -
-
+
+
MG132
IL-1β β β β
p-Iκ κ κ κBα α α α
Iκ κ κ κBα α α α
*
**
IL-1β β β β
R
e
l
a
t
i
v
e
 
Q
u
a
n
t
i
t
y
 
o
f
 
T
L
R
2
 
m
R
N
A
 
CON Iκ κ κ κBα α α αDN IKKßDN –
6
0
3
2
4
5
1
*
** **
MG132  
    +
 IL-1β β β β
CON IL-1β β β β MG132  
R
e
l
a
t
i
v
e
 
Q
u
a
n
t
i
t
y
 
o
f
 
T
L
R
2
 
m
R
N
A
 
0
5
10
15 NHBE
-
-
+
+ -
-
+
+
MG132
IL-1β β β β
**
*
NHBE
CON Iκ κ κ κBα α α αDN IKKßDN –
IL-1β β β β
R
e
l
a
t
i
v
e
 
Q
u
a
n
t
i
t
y
 
o
f
 
T
L
R
2
 
m
R
N
A
 
8
0
4
2
6
10
** **
*BMC Molecular Biology 2004, 5 http://www.biomedcentral.com/1471-2199/5/2
Page 5 of 16
(page number not for citation purposes)
regulating the expression of large numbers of genes
involved in immunity and inflammation and the fact that
NF-κB can be activated by IL-1β, we investigated the
involvement of NF-κB signaling in TLR2 induction. We
first investigated whether IL-1β induces phosphorylation
and degradation of IκBα by performing Western blot
analysis using antibodies against phosphorylated and
total IκBα, respectively. IκBα phosphorylation became
evident at 5 min, peaked at 10 min, and declined thereaf-
ter (Figure 2a). Consistent with this result, the IL-1β-
induced degradation of IκBα was observed at 5 min and
returned to baseline levels by 3 h (Figure 2a). We then
determined the requirement of IκBα degradation in IL-β-
induced TLR2 expression. As shown in Figure 2b, MG132,
a proteasome inhibitor that prevents the degradation of
IκBα, completely blocked the NF-κB nuclear translocation
induced by IL-1β (middle panel). As expected, the IL-1β-
induced IκBα degradation was also blocked by MG132
(Figure 2b, upper panel). Accordingly, phosphorylated
IκBα was no longer degraded in the presence of MG-132,
thus persisting in the cytoplasm. Concomitantly, IL-1β-
induced TLR2 up-regulation was also inhibited by MG132
(Figure 2b, lower panel). To further confirm the involve-
ment of IκBα degradation in IL-1β-induced TLR2 expres-
sion, we next transfected HeLa cells with a transdominant
mutant of IκBα (S32A, S36A). As shown in Figure 2c,
overexpression of the IκBα transdominant mutant inhib-
ited IL-1β-induced TLR2 up-regulation. On the basis of a
recent report that IκB kinase β (IKKβ) acts as an immedi-
ate kinase of IκBα, we investigated the role of IKKβ in IL-
1β-induced TLR2 induction. Overexpression of a domi-
nant-negative mutant form of IKKβ inhibited IL-1β-
induced TLR2 up-regulation (Figure 2c). Likewise, the
involvement of IKKβ-IκBα in IL-1β-induced TLR2 expres-
sion was also confirmed in human primary bronchial epi-
thelial NHBE cells (Figure 2d and 2e). Taken together,
these data demonstrate that IKKβ-IκBα-dependent activa-
tion of NF-κB is required for IL-1β-induced TLR2 up-regu-
lation in human epithelial cells.
Activation of MKK3/6-p38 α/β MAPK pathway is 
negatively involved in IL-1β-induced TLR2 expression
Many cellular stress stimuli can simultaneously activate
both NF-κB and p38 MAPK modules. Because of this over-
lap as well as the evidence for the activation of p38 by IL-
1β [17], we explored the possible involvement of p38
MAPK pathway in IL-1β-induced TLR2 up-regulation. We
first confirmed whether IL-1β induces phosphorylation of
p38 MAPK in HeLa cells. As shown in Figure 3a, p38
MAPK is strongly phosphorylated by IL-1β in a time-
dependent manner. To determine whether the activation
of p38 MAPK is involved in IL-1β-induced TLR2 up-regu-
lation, we assessed the effect of the pyridinyl imidazole,
SB203580, a highly specific inhibitor for p38 MAPK, on
TLR2 induction. Interestingly, SB203580 greatly
enhanced IL-1β-induced TLR2 up-regulation, suggesting
that activation of p38 MAPK is negatively involved in IL-
1β-induced TLR2 expression (Figure 3b). Moreover, over-
expression of a dominant-negative mutant form of either
p38α [fp38α(AF)] or p38β [fp38β(AF)] also enhanced the
IL-1β-induced TLR2 expression, whereas overexpression
of a wild-type p38α or p38β reduced it, thereby confirm-
ing the negative involvement of p38 MAPK in HeLa cells
(Figure 3c). Similarly, SB203580 and overexpression of a
dominant-negative mutant form of either
p38α[fp38α(AF)] or p38β [fp38β(AF)] also enhanced the
IL-1b-induced TLR2 expression in primary bronchial epi-
thelial NHBE cells (Figure 3d and 3e). As immediate
upstream kinases of p38 α and β, two MAPK kinases
(MKK3 and MKK6) have been identified [18-20]. To fur-
ther investigate whether activation of MKK3/6 is also neg-
atively involved in IL-1β-induced TLR2 expression, we
first sought to determine whether IL-1β induces activation
of MKK3/6. As shown in Figure 3f, IL-1β strongly induced
phosphorylation of MKK3/6 in HeLa cells. We next
investigated the effect of overexpressing a dominant-neg-
ative mutant form of either MKK3 [MKK3b(A)] or MKK6
[MKK6b(A)] on TLR2 induction in HeLa cells. The IL-1β-
induced TLR2 up-regulation was enhanced by blocking
MKK3/6 signaling (Figure 3g). Similar results were also
obtained in primary NHBE cells (Figure 3h). Collectively,
our data suggest that activation of MKK3/6-p38 α/β
MAPK signaling pathway is negatively involved in IL-1β-
induced TLR2 up-regulation in human epithelial cells.
Activation of MEKK1-MKK4/7-JNK1/2 pathway is also 
negatively involved in IL-1β-induced TLR2 expression
Besides the p38 MAPK pathway, the c-Jun N-terminal
kinase (JNK) pathway represents another key MAPK path-
way involved in the regulation of immune response genes.
JNK is activated by a variety of environmental stresses
including pro-inflammatory cytokine IL-1β [18]. There-
fore, we next sought to investigate the involvement of JNK
pathway in IL-1β-induced TLR2 expression. We first deter-
mined whether IL-1β induces phosphorylation of JNK in
HeLa cells. As shown in Figure 4a, JNK is strongly phos-
phorylated by IL-1β in a time-dependent manner. To
determine the involvement of JNK pathway in TLR2 up-
regulation, a dominant-negative mutant form of either
JNK1 [JNK1(AF)] or JNK2 [JNK2(AF)] was transfected
into HeLa cells. Overexpression of a dominant-negative
mutant of either JNK1 or JNK2 enhanced the IL-1β-
induced TLR2 expression (Figure 4b). Similar result was
also observed in primary NHBE cells (Figure 4c). These
results suggest that JNK1/2 pathway is also negatively
involved in IL-1β-induced TLR2 expression in human epi-
thelial cells.
On the basis that JNK activation is mediated by two
upstream MAPK kinases (MKKs), MKK4 and MKK7, andBMC Molecular Biology 2004, 5 http://www.biomedcentral.com/1471-2199/5/2
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Activation of MKK3/6-p38 α/β MAPK pathway is negatively involved in IL-1β-induced TLR2 expression Figure 3
Activation of MKK3/6-p38 α/β MAPK pathway is negatively involved in IL-1β-induced TLR2 expression. A, IL-1β 
induces p38 phosphorylation in HeLa cells in a time-dependent manner as assessed by Western blot analysis. Cells were 
treated with IL-1β (10 ng/ml) for the indicated time periods. B, SB203580 greatly enhances IL-1β-induced TLR2 up-regulation 
in HeLa cells. Cells were pretreated for 2 h with the indicated concentration of SB203580 prior to treatment with IL-1β (10 
ng/ml) for 3 h. Values are the mean ± SD; n = 3. The symbols indicate results significantly different (p < 0.01) from unstimulated 
condition (*) and IL-1β-stimulated condition (without SB203580)(**). C, Overexpression of a dominant-negative mutants of 
either p38α [fp38α(AF)] or p38β [fp38β (AF)] enhances, whereas overexpression of a wild-type p38α or p38β reduces, the IL-
1β-induced TLR2 expression in HeLa cells. Cells were treated with IL-1β (10 ng/ml) for 3 h. Values are the mean ± SD; n = 3. 
The symbols indicate results significantly different (p < 0.01) from unstimulated condition (*) and IL-1β-stimulated condition 
(without wild-type or dominant-negative construct)(**). D, SB203580 greatly enhances IL-1β-induced TLR2 up-regulation in 
NHBE cells. Cells were pretreated for 2 h with SB203580 (20 µM) prior to treatment with IL-1β (10 ng/ml) for 3 h. Values are 
the mean ± SD; n = 3. The symbols indicate results significantly different (p < 0.01) from unstimulated condition (*) and IL-1β-
stimulated condition (without SB203580)(**). E, Overexpression of a dominant-negative mutant of p38α or p38β enhances the 
IL-1β-induced TLR2 expression in NHBE cells. Values are the mean ± SD; n = 3. The symbols indicate results significantly dif-
ferent (p < 0.01) from unstimulated condition (*) and IL-1β-stimulated condition (without dominant negative construct)(**). F, 
IL-1β induces MKK3/6 phosphorylation in HeLa cells. Cells were treated with IL-1β (10 ng/ml) for 20 min. G, Overexpression 
of a dominant-negative mutant form of either MKK3 [MKK3b (A)] or MKK6 [MKK6b (A)] also enhances IL-1β-induced TLR2 
up-regulation in HeLa cells. Cells were treated with IL-1β (10 ng/ml) for 3 h. Values are the mean ± SD; n = 3. The symbols 
indicate results significantly different (p < 0.01) from unstimulated condition (*) and IL-1β-stimulated condition (without domi-
nant-negative construct)(**). H, Overexpression of a dominant-negative mutant form of either MKK3 or MKK6 also enhances 
IL-1β-induced TLR2 up-regulation in NHBE cells. Cells were treated with IL-1β (10 ng/ml) for 3 h. Values are the mean ± SD; n 
= 3. The symbols indicate results significantly different (p < 0.01) from unstimulated condition (*) and IL-1β-stimulated condi-
tion (without dominant-negative construct)(**).
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Activation of MEKK1-MKK4/7-JNK1/2 pathway is also negatively involved in IL-1β-induced TLR2 expression Figure 4
Activation of MEKK1-MKK4/7-JNK1/2 pathway is also negatively involved in IL-1β-induced TLR2 expression. A, 
IL-1β induces JNK phosphorylation in HeLa cells in a time-dependent manner as assessed by Western blot analysis. Cells were 
treated with IL-1β (10 ng/ml) for the indicated time periods. B, Overexpression of a dominant-negative mutants of either JNK1 
[JNK1 (AF)] or JNK2 [JNK2 (AF)] enhances the IL-1β-induced TLR2 expressionin HeLa cells. Values are the mean ± SD; n = 3. 
The symbols indicate results significantly different (p < 0.01) from unstimulated condition (*) and IL-1β-stimulated condition 
(without dominant-negative construct)(**). C, Overexpression of a dominant-negative mutant of either JNK1 or JNK2 
enhances the IL-1β-induced TLR2 expression in NHBE cells. Values are the mean ± SD; n = 3. The symbols indicate results sig-
nificantly different (p < 0.01) from unstimulated condition (*) and IL-1β-stimulated condition (without dominant-negative con-
struct)(**). D, IL-1β induces MKK4 phosphorylation in HeLa cells. Cells were treated with IL-1β (10 ng/ml) for 20 min. E, 
Overexpression of a dominant-negative mutant form of MKK4 or MKK7 or MEKK1 enhances IL-1β-induced TLR2 up-regula-
tion in HeLa cells. Values are the mean ± SD; n = 3. The symbols indicate results significantly different (p < 0.01) from unstim-
ulated condition (*) and IL-1β-stimulated condition (without dominant negative construct)(**). F, Overexpression of a 
dominant-negative mutant of MKK4 or MKK7 or MEKK1 also enhances IL-1β-induced TLR2 up-regulation in NHBE cells. Val-
ues are the mean ± SD; n = 3. The symbols indicate results significantly different (p < 0.01) from unstimulated condition (*) and 
IL-1β-stimulated condition (without dominant-negative construct)(**). For all the TLR2 mRNA measurement, cells were 
treated with IL-1β (10 ng/ml) for 3 h.
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that both MKKs are activated by the further upstream
MAPK/Erk kinase kinase 1 (MEKK1), we next sought to
investigate whether the MEKK1-MKK4/7 signaling path-
way is also negatively involved in TLR2 induction. We first
confirmed whether MKK4 is activated by IL-1β in HeLa
cells. Figure 4d showed a strong phosphorylation of
MKK4 induced by IL-1β. To further determine the involve-
ment of MEKK1-MKK4/7 pathway, HeLa cells were trans-
fected with a dominant-negative mutant of either MKK4
or MKK7 or MEKK1. As shown in Figure 4e, overexpres-
sion of these dominant-negative mutants enhanced IL-1β-
induced TLR2 expression (Figure 4e). Similar results were
also observed in primary human bronchial epithelial
NHBE cells (Figure 4f). Together, these results indicate
that activation of MEKK1-MKK4/7-JNK1/2 signaling path-
way is also negatively involved in IL-1β-induced TLR2
expression in human epithelial cells.
Glucocorticoids synergistically enhance IL-1β-induced 
TLR2 expression likely via negative cross-talk with MAPK 
p38 and JNK pathways
Glucocorticoids are well known for their anti-inflamma-
tory, immune suppressive and anti-allergic activities [21].
They exert their anti-inflammatory effects by inhibiting
the activity of transcription factors such as AP-1 and NF-
κB that are involved in regulation of a variety of genes
involved in the inflammatory responses [22,23]. Because
we have shown that activation of NF-κB is required for IL-
1β-induced TLR2 expression, it is logical that glucocorti-
coids should suppress the IL-1β-induced TLR2 up-regula-
tion. Surprisingly, dexamethasone (DEX), a
glucocorticoid analog, synergistically enhanced IL-1β-
induced TLR2 expression at the mRNA level in both HeLa
cells and primary human bronchial epithelial NHBE cells
(Figure 5a and 5b). The enhancing effect of DEX on TLR2
up-regulation was counteracted by RU486, a synthetic
antiglucocorticoid that acts as a competitor against bind-
ing to the glucocorticoid receptor (GR), suggesting the
enhancing effect of DEX is mediated by the GR. Concom-
itantly, Western blot analysis showed that IL-1β also syn-
ergistically enhanced TLR2 expression at protein level,
thereby confirming that up-regulation of TLR2 mRNA is
indeed accompanied by elevated TLR2 protein (Figure
5c). These results indicate that DEX synergistically
enhances IL-1β-induced TLR2 up-regulation at both
mRNA and protein levels in human epithelial cells.
Because glucocorticoids have been shown to inhibit a
number of MAPK family members, we next sought to
determine whether DEX inhibits the IL-1β-induced activa-
tion of p38 or JNK by performing Western blot analysis.
As shown in Figure 5d and 5e, DEX inhibited IL-1β-
induced phosphorylation of both p38 and JNK, but not
MKK3/6 or MKK4 and the inhibitory effects of DEX were
blocked by GR antagonist RU486. Therefore, it is likely
that DEX may synergistically enhance IL-1β-induced TLR2
up-regulation via negative cross-talk with p38 and JNK,
but not their upstream kinases MKK3/6 or MKK4.
Glucocorticoids may enhance IL-1β-induced TLR2 up-
regulation via up-regulation of MAP kinase phosphatase 1 
(MKP-1)
Based on recent reports that glucocorticoids inhibit the
activation of p38 and JNK by up-regulating the expression
of MKP-1 [24-26], we investigated whether MKP-1 is
involved in the enhancing effect of DEX on IL-1β-induced
TLR2 expression. We first confirmed that MKP-1 protein
expression is indeed induced by DEX, and the DEX-
induced MKP-1 expression was counteracted by the GR
antogonist RU486 in HeLa cells (Figure 6a). We next
investigated whether overexpression of MKP-1 mimics
DEX. As expected, overexpression of wild-type MKP-1
inhibited IL-1β-induced p38 and JNK phosphorylation,
whereas mutated MKP-1 had almost no effect on their
phosphorylation (Figure 6b). Moreover, overexpression
of wild-type MKP-1 enhanced IL-1β-induced TLR2 expres-
sion, whereas mutated MKP-1 slightly inhibited the TLR2
induction in both HeLa cells (Figure 6c) and primary
NHBE cells (Figure 6d). Thus, it is clear that overexpres-
sion of wild-type MKP-1 mimics the enhancing effect of
DEX on IL-1β-induced TLR2 up-regulation, supporting
the hypothesis that glucocorticoids may enhance the IL-
1β-induced TLR2 expression via a MKP-1-dependent inhi-
bition of p38 and JNK.
Inhibition of MKP-1 expression attenuates 
glucocorticoids-mediated inhibition of IL-1β-induced p38 
and JNK phosphorylation and enhancement of TLR2 
expression
Having demonstrated that overexpression of MKP-1
inhibits IL-1β-induced p38 and JNK phosphorylation and
enhances TLR2 induction, we next sought to determine
whether inhibition of MKP-1 expression blocks the
enhancing effect of DEX on TLR2 induction via negative
cross-talks with p38 and JNK. We first confirmed that Ro-
31-8220, an inhibitor for MKP-1 expression, inhibited
DEX-mediated MKP-1 up-regulation at protein level (Fig-
ure 7a). We then determined whether Ro-31-8220 blocks
the DEX-mediated inhibition of IL-1β-induced p38 or
JNK phosphorylation. As shown in Figure 7b, the inhibi-
tory effect of DEX on IL-1β-induced phosphorylation of
p38 or JNK was blocked by Ro-31-8220. Moreover, DEX-
mediated synergistic enhancement of IL-1β-induced TLR2
expression was greatly inhibited by Ro-31-8220 in both
HeLa cells (Figure 7c) and primary NHBE cells (Figure
7d). These data suggest that DEX-mediated synergistic
enhancement of TLR2 induction is mediated by up-regu-
lation of MKP-1.BMC Molecular Biology 2004, 5 http://www.biomedcentral.com/1471-2199/5/2
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Glucocorticoids synergistically enhance IL-1β-induced TLR2 up-regulation via negative cross-talks with MAPK p38 and JNK1/2  pathways Figure 5
Glucocorticoids synergistically enhance IL-1β-induced TLR2 up-regulation via negative cross-talks with MAPK 
p38 and JNK1/2 pathways. A, Dexamethasone (DEX) synergistically enhances IL-1β-induced TLR2 up-regulation and RU486 
counteracts the enhancing effect of DEX on IL-1β-induced TLR2 up-regulation at mRNA level in HeLa cells. HeLa cells were 
first pretreated with RU486 (10-6 M) for 2 h and were then treated with DEX (10-6 M) for 2 h. The cells were stimulated with 
IL-1β (10 ng/ml) for 3 h, and the TLR2 mRNA levels were then assessed by real-time quantitative PCR. Values are the mean ± 
SD; n = 3. The symbols indicate results significantly different (p < 0.01) from unstimulated condition (*) and IL-1β-DEX-stimu-
lated condition (without RU486)(**). B, DEX (10-6 M) synergistically enhances IL-1β-induced TLR2 up-regulation and RU486 
(10-6 M) counteracts the enhancing effect of DEX on IL-1β-induced TLR2 up-regulation at mRNA level in NHBE cells. Cells 
were first pretreated with RU486 (10-6 M) for 2 h and were then treated with DEX (10-6 M) for 2 h. The cells were stimulated 
with IL-1β (10 ng/ml) for 3 h, and the TLR2 mRNA levels were then assessed. Values are the mean ± SD; n = 3. The symbols 
indicate results significantly different (p < 0.01) from unstimulated condition (*) and IL-1β-DEX-stimulated condition (without 
RU486)(**). C, Glucocorticoids also synergistically enhance the induction of TLR2 at protein level in HeLa cells. HeLa cells 
were first treated for 2 h with DEX (10-6 M). The cells were then stimulated with IL-1β (10 ng/ml) for 5 h. Protein level of 
TLR2 was assessed by Western blot analysis using an anti-hTLR2 antibody. β-Actin was used as a protein loading control. D, 
DEX inhibits IL-1β-induced phosphorylation of p38, but not MKK3/6, and the inhibitory effect of DEX is blocked by RU486. 
HeLa cells were first treated with RU486 (10-6 M) for 2 h and were then treated with DEX (10-6 M) for 2 h. The cells were 
stimulated with IL-1β (10 ng/ml) for 20 min. IL-1β-induced phosphorylation of p38 MAPK and MKK3/6 was then assessed by 
Western blot analysis. E, DEX inhibits IL-1β-induced phosphorylation of JNK, but not MKK4, and the inhibitory effect of DEX 
is blocked by RU486. HeLa cells were first treated with RU486 (10-6 M) for 2 h and were then treated with DEX (10-6 M) for 2 
h. The cells were stimulated with IL-1β (10 ng/ml) for 20 min.
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Glucocorticoids enhance IL-1β-induced TLR2 up-regulation likely via upregulation of MKP-1 Figure 6
Glucocorticoids enhance IL-1β-induced TLR2 up-regulation likely via upregulation of MKP-1. A, MKP-1 protein 
expression is induced by DEX and the MKP-1 induction is counteracted by RU486 in HeLa cells. HeLa cells were first treated 
with RU486 (10-6 M) for 2 h and were then treated with DEX (10-6 M) for 2 h. Protein level of MKP-1 was assessed by Western 
blot analysis. β-Actin was used as a protein loading control. B, Overexpression of wild-type MKP-1 inhibits IL-1β-induced p38 
and JNK phosphorylation, whereas overexpression of MKP-1 mutant has almost no effect on IL-1β-induced p38 and JNK phos-
phorylation. Transfected HeLa cells were stimulated with IL-1β (10 ng/ml) for 20 min. IL-1β-induced phosphorylation of p38 
MAPK and JNK was then assessed by Western blot analysis. C, Overexpression of wild-type MKP-1 enhances the IL-1β-
induced TLR2 expression, whereas overexpression of MKP-1 mutant has almost no effect on the IL-1β-induced TLR2 expres-
sion in HeLa cells. Values are the mean ± SD; n = 3. The symbols indicate results significantly different (p < 0.01) from unstim-
ulated condition (*) and IL-1β-stimulated condition (without MKP-1 construct)(**). D, Overexpression of wild-type MKP-1 
enhances the IL-1β-induced TLR2 expression, whereas overexpression of MKP-1 mutant has almost no effect on the IL-1β-
induced TLR2 expression in NHBE cells. Values are the mean ± SD; n = 3. The symbols indicate results significantly different (p 
< 0.01) from unstimulated condition (*) and IL-1β-stimulated condition (without MKP-1 construct)(**). For all of the TLR2 
mRNA measurement, cells were treated with IL-1β (10 ng/ml) for 3 h.
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Inhibition of MKP-1 attenuates dexamethasone-mediated inhibition of IL-1β-induced p38 and JNK phosphorylation and  enhancement of TLR2 expression Figure 7
Inhibition of MKP-1 attenuates dexamethasone-mediated inhibition of IL-1β-induced p38 and JNK phosphor-
ylation and enhancement of TLR2 expression. A, MKP-1 protein expression is induced by DEX and the MKP-1 induction 
is inhibited by Ro-31-8220, an inhibitor for MKP-1 expression, in HeLa cells. HeLa cells were first treated with Ro-31-8220 (10-
6 M) for 2 h, and were then treated with DEX (10-6 M) for 2 h. Protein level of MKP-1 was assessed by Western blot analysis. 
β-Actin was used as a protein loading control. B, The inhibitory effect of DEX on IL-1β-induced p38 or JNK phosphorylation is 
antagonized by Ro-31-8220. HeLa cells were first treated with Ro-31-8220 (10-6 M) for 2 h and were then treated with DEX 
(10-6 M) for 2 h. The cells were stimulated with IL-1β (10 ng/ml) for 20 min. IL-1β-induced phosphorylation of p38 or JNK was 
then assessed by Western blot analysis. C, DEX-mediated enhancement of IL-1β-induced TLR2 expression is greatly inhibited 
by Ro-31-8220 in HeLa cells. HeLa cells were first treated with Ro-31-8220 (10-6 M) for 2 h and were then treated with DEX 
(10-6 M) for 2 h. The cells were stimulated with IL-1β (10 ng/ml) for 3 h, and the TLR2 mRNA levels were then assessed by 
real-time quantitative PCR. Values are the mean ± SD; n = 3. The symbols indicate results significantly different (p < 0.01) from 
unstimulated condition (*) and IL-1β-DEX-stimulated condition (without Ro-31-8220)(**). D, DEX-mediated enhancement of 
IL-1β-induced TLR2 expression is greatly inhibited by Ro-31-8220 in NHBE cells. NHBE cells were first treated with Ro-31-
8220 (10-6 M) for 2 h and were then treated with DEX (10-6 M) for 2 h. The cells were stimulated with IL-1β (10 ng/ml) for 3 h. 
Values are the mean ± SD; n = 3. The symbols indicate results significantly different (p < 0.01) from unstimulated condition (*) 
and IL-1β-DEX-stimulated condition (without Ro-31-8220)(**). E, Overexpression of the antisense MKP-1 inhibited MKP-1 
protein expression, but not MKP-2 or MKP-3 expression. Transfected HeLa cells were treated with DEX (10-6 M) for 2 h. Pro-
tein level of MKP-1, -2 and -3 were assessed by Western blot analysis. β-Actin was used as a protein loading control. F, Over-
expression of antisense MKP-1 blocks the inhibitory effect of DEX on IL-1β-induced p38 or JNK phosphorylation in HeLa cells. 
Transfected HeLa cells were first pretreated with DEX (10-6 M) for 2 h. The cells were then stimulated with IL-1β (10 ng/ml) 
for 20 min. IL-1β-induced phosphorylation of p38 or JNK was next assessed by Western blot analysis. G, DEX-mediated 
enhancement of IL-1β-induced TLR2 expression is attenuated by overexpression of antisense MKP-1 in HeLa cells. Transfected 
HeLa cells were pretreated with DEX (10-6 M) for 2 h, and then stimulated with IL-1β (10 ng/ml) for 3 h. Values are the mean 
± SD; n = 3. The symbols indicate results significantly different (p < 0.01) from unstimulated condition (*) and IL-1β-DEX-stim-
ulated condition (without antisense MKP-1 construct)(**). H, DEX-mediated enhancement of IL-1β-induced TLR2 expression 
is also attenuated by overexpression of antisense MKP-1 in NHBE cells. Transfected cells werepretreated with DEX (10-6 M) 
for 2 h, and then stimulated with IL-1β (10 ng/ml) for 3 h. Values are the mean ± SD; n = 3. The symbols indicate results signif-
icantly different (p < 0.01) from unstimulated condition (*) and IL-1β-DEX-stimulated condition (without antisense MKP-1 
construct)(**).
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To further confirm whether the up-regulation of MKP-1
by glucocorticoids is indeed required for the enhance-
ment of IL-1β-induced TLR2 expression, we investigated
the effect of overexpressing an antisense full-length MKP-
1 construct on the glucocorticoid-mediated enhancement
of TLR2 induction [27]. As shown in Figure 7e, we first
confirmed that overexpression of the antisense MKP-1
construct specifically inhibited MKP-1 protein expression,
but not MKP-2 or MKP-3 expression. In addition, overex-
pression of the antisense MKP-1 construct antagonized
the inhibitory effect of DEX on IL-1β-induced phosphor-
ylation of p38 or JNK (Figure 7f). Moreover, overexpres-
sion of the same antisense MKP-1 also inhibited the DEX-
mediated enhancement of IL-1β-induced TLR2 expression
in both HeLa cells and primary human bronchial epithe-
lial NHBE cells (Figure 7g and 7h). Taken together, our
data demonstrate that glucocorticoids synergistically
enhance IL-1β-induced TLR2 expression via up-regulation
of MKP-1 that, in turn, leads to dephosphorylation and
inactivation of p38 and JNK, the negative regulators for
TLR2 expression in human epithelial cells.
Discussion
Despite the importance of glucocorticoids in suppressing
immune and inflammatory responses, their role in
enhancing host immune and defense response against
invading bacterial pathogens is poorly understood
[13,14,28,29]. Although there are reports that glucocorti-
coids may have a beneficial role in certain bacterial infec-
tions, the molecular basis for their beneficial effects still
remains unclear. In the present study, we provided evi-
dence that glucocorticoids synergistically enhance the
TLR2 expression, a key receptor that has been shown to
play a crucial role in host defense response, as evidenced
by the studies of TLR2 knockout mice showing decreased
survival after infection with Gram-positive S. aureus [11].
Thus, it appears that glucocorticoids may not only sup-
press but also likely enhance host immune and defense
response. In addition, our study may provide the molecu-
lar basis for the explanation of the beneficial role of glu-
cocorticoids in certain bacterial infections. Given the fact
that TLR2 expression is low in unstimulated epithelial
cells, the synergistic enhancement of IL-1β-induced TLR2
expression by glucocorticoids will probably contribute to
the accelerated immune response by epithelial cells as
well as resensitization of epithelial cells to invading path-
ogens. It should be noted that glucocorticoids enhance
the TLR2 expression induced not only by IL-1β, but also
by a variety of other pathogenic inducers including the
Gram-negative bacterium nontypeable Haemophilus influ-
enzae, the Gram-positive bacterium Streptococcus pneumo-
niae, and the proinflammatory cytokines TNF-α and IL-1α
(data not shown). Therefore, up-regulation of the host
defense receptor, TLR2, may be one of the important pos-
itive immune-regulatory mechanisms widely involved in
the glucocorticoid-mediated host defense against many
microbial pathogens. Our studies may bring new insights
into the novel role of glucocorticoids in orchestrating and
optimizing immune functions, including host defense,
during bacterial infections.
Another interesting finding in this study is that glucocor-
ticoids synergistically enhance the IL-1β-induced TLR2
expression via a MKP-1-mediated inactivation of both
MAPK p38 and JNK, the negative regulators for TLR2
induction. Although several MAPKs have been identified
as potential targets for negative regulation by glucocorti-
coids [25,30-36], the signaling mechanisms underlying
the inhibition of MAPKs by glucocorticoids still remain
largely unknown. Our finding that glucocorticoids inhibit
the IL-1β-induced phosphorylation and activation of
MAPKs p38 and JNK via up-regulation of MKP-1 may
enhance our understanding of the signaling mechanisms
underlying the glucocorticoid-mediated attenuation of
MAPKs. In agreement with recent reports that glucocorti-
coids inhibit p38 via up-regulation of MKP-1 [24,26], our
data showed that glucocorticoids enhanced IL-1β-induced
TLR2 expression via up-regulating MKP-1 expression, that,
in turn, leads to the dephosphorylation and inactivation
of p38 in HeLa cells and primary NHBE cells. However,
our finding that glucocorticoids inhibit the IL-1β-induced
phosphorylation of JNK via an up-regulation of MKP-1 is
rather unexpected, because it is in sharp contrast with the
previous report that glucocorticoid-mediated inhibition
of JNK does not require any de novo protein synthesis and
independent of the transactivation function of GR [31].
Similar to the glucocorticoid-mediated inactivation of
p38, glucocorticoids require ongoing MKP-1 synthesis to
inhibit phosphorylation of ERK1/2 [25,37]. Hence, mul-
tiple signaling mechanisms are likely to underlie the regu-
lation of MAPKs by glucocorticoids.
The molecular mechanisms underlying p38 and JNK-
mediated inhibition of TLR2 induction by IL-1β still
remain unclear. The human TLR2 promoter contains mul-
tiple transcription factor binding elements including Sp1
and Ets-1 [38]. Sp1 and Ets-1 have been shown to be reg-
ulated by p38 signaling pathway [39,40]. Activation of
Sp1 and Ets family through JNK has been also reported
[41,42]. Thus, Sp1 and Ets-1 could be involved in p38 and
JNK-mediated inhibition of TLR2 expression. TLR2 pro-
moter region also contains some uncharacterized regula-
tory elements [38]. These elements may also play a role in
transcriptional inhibition of TLR2 mediated by p38 and
JNK signaling. In addition to these transcription factors,
the possible involvement of the regulation of mRNA sta-
bility by p38 and JNK can not be ruled out because both
have been shown to be involved in regulating the mRNA
stability of certain genes [43-46].BMC Molecular Biology 2004, 5 http://www.biomedcentral.com/1471-2199/5/2
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Although we have shown the involvement of multiple sig-
naling pathways including the positive IKKβ-IκBα-
dependent NF-κB pathway and the negative MKK3/6-p38
α/β and MEKK1-MKK4/7-JNK1/2 pathways, our data do
not preclude the involvement of other signaling mecha-
nisms such a direct transcriptional activation of TLR2 by
glucocorticoids, or direct cross-talk between GR and other
transcription factors that can be activated by the above sig-
naling pathways. Future studies will focus on elucidating
the signaling mechanisms underlying the glucocorticoid-
mediated synergistic enhancement of IL-1β-induced TLR2
at the transcriptional level by taking advantage of the
recent success in cloning the regulatory region of human
TLR2. In addition, the role of MKP-1 in mediating the
enhancement of TLR2 induction by glucocorticoids will
also be confirmed in vivo by using an MKP-1 knockout
mouse strain. Moreover, it is also interesting to determine
whether glucocorticoids also enhance antibacterial
defense responses.
Conclusion
We provided direct evidence that glucocorticoids synergis-
tically enhance the IL-1β-induced TLR2 expression, a key
host defense receptor, via specific up-regulation of MKP-1
expression, which, in turn, leads to the inactivation of
both p38 and JNK signaling pathways, the negative regu-
lators for TLR2 induction (Figure 8). These studies may
bring new insights into the role of glucocorticoids in
enhancing host defense response against bacterial inva-
sion and lead to novel therapeutic intervention for modu-
lating host defense and immune responses in bacterial
infections.
Methods
Reagents
Human IL-1β was purchased from PIERCE ENDOGEN
(Woburn, MA). MG-132, SB203580 and Ro-31-8220 were
purchased from Calbiochem (La Jolla, CA). Dexametha-
sone and RU486 were purchased from Sigma (St. Louis,
MO).
Cell culture
The human cervix epithelial cell line, HeLa, was main-
tained as described [6]. Primary human bronchial epithe-
lial cells (NHBE) (Clonetics, Walkersville, MD) were
maintained in Bronchial Epithelial Basal Medium
(BEBM) (Clonetics) according to the manufacturer's
instructions.
Real-time quantitative PCR analysis of TLR2 and TLR4
Total RNA was isolated from the cells using a TRIzol Rea-
gent (Invitrogen Corporation, Carlsbad, CA) following
manufacturer's instruction. For the RT reaction, TaqMan
Reverse Transcription Regents (Applied Biosystems, Foster
City, CA) were used. The real-time quantitative PCR was
performed using an ABI 7700 sequence detector (Applied
Biosystems). The primers and probes used for the PCR
amplification of TLR2 were; p r i m e r s (5'-GGCCAG-
CAAATTACCTGTGTG-3' a n d 5'-AGGCGGACATCCT-
GAACCT-3') and a probe (5'-
TCCATCCCATGTGCGTGGCC-3'). The primers and
probes used for the PCR amplification of TLR4 were;
primers (5'-CCAGTGAGGATGATGCCAGGAT-3' and 5'-
GCCATGGCTGGGATCAGAGT-3') and a probe (5'-
TGTCTGCCTCGCGCCTGGC-3'). All primers and probes
were synthesized by Applied Biosystems Custom Oligo
Synthesis Service. Relative quantity of TLR2 and TLR4
mRNA were obtained using Comparative CT Method, and
was normalized using Pre-Developed TaqMan Assay Rea-
gent Human Cyclophilin (Applied Biosystems) as an
endogenous control as previously described [24].
Plasmids and transfections
The expression plasmids IκBα(S32/36A), IKKβ (K49A),
fp38α (AF) and wild-type (WT), fp38β2 (AF) and WT,
MKK3b (A), MKK6b (A), JNK1 (AF), JNK2 (AF), MKK4
DN, MKK7 DN and MEKK1 DN were previously described
[6,47]. The expression plasmid of the wild-type and
mutant MKP-1 were kindly provided by Dr. N. Tonks
(Cold Spring Harbor Laboratory, NY) [48]. The antisense
full-length MKP-1 construct was kindly provided by Dr.
Desbois-Mouthon (INSERM U-402, Faculté de Médecine
Saint-Antoine, 75571 Paris, France) and was described
previously [27]. All transient transfections were carried
out in duplicate for RT-PCR analysis using TransIT-LT1
reagent (Mirus, Madison, WI) following manufacturer's
instruction, unless otherwise indicated. In all transfec-
tions with expression plasmids of signaling molecules, an
empty vector was used as a control.
Western Blot analysis
Phosphorylation of IκBα, JNK, p38, MKK4 and MKK3/6
was assessed using antibodies against phospho-IκBα
(Ser32), IκBα, phospho-JNK (Thr183/Tyr185), JNK,
phospho-p38 (Thr180/182), p38, phospho-MKK4
(Thr261), phospho-MKK3/MKK6 (Ser189/207) and
MKK3 (New England Biolabs, Beverly, MA). Anti-MKK4
(K-18) was purchased from Santa Cruz Biotechnology,
Inc. Santa Cruz, CA). Phosphorylation of of IκBα, JNK,
p38, MKK4 and MKK3/6 was detected as described [49].
Anti-MKP-1 (V-15), anti-MKP-2 (H-67) and anti-MKP-3
(C-20) antibodies were purchased from Santa Cruz, and
used to assess protein expression. TLR2 expression was
assessed with an anti-TLR2 antibody (Imgenex Corpora-
tion, San Diego, CA). Monoclonal anti-β-Actin antibody
(Sigma) was used as a protein loading control for Western
blot analyses of MKP-1, MKP-2, MKP-3 and TLR2.BMC Molecular Biology 2004, 5 http://www.biomedcentral.com/1471-2199/5/2
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Schematic representation of the signaling pathways involved in glucocorticoid-mediated enhancement of IL-1β-induced TLR2  expression via MKP-1-dependent inhibition of p38 and JNK in human epithelial cells Figure 8
Schematic representation of the signaling pathways involved in glucocorticoid-mediated enhancement of IL-
1β-induced TLR2 expression via MKP-1-dependent inhibition of p38 and JNK in human epithelial cells. IL-1β up-
regulates TLR2 expression via a positive IKKβ-IκBα-dependent NF-κB pathway and negative MKK3/6-p38α/β and MEKK1-
MKK4/7-JNK1/2 signaling pathways. Glucocorticoids synergistically enhance IL-1β-induced TLR2 expression via up-regulation 
of MKP-1 that, in turn, leads to dephosphorylation and inactivation of p38 and JNK pathways, the negative regulators for TLR2 
expression. Abbreviations: DEX, dexamethasone; GR, glucocorticoids receptor; IκBα, Inhibitor of NF-κBα ; IKKβ, IκB kinase β 
; IL-1β, interleukin 1 β ; JNK, c-Jun N-terminal kinase;MAPK, mitogen-activated protein kinase; MKK, MAPK kinase; MEKK1, 
MAPK/Erk kinase kinase 1; MKP-1, MAP kinase phosphatase-1; NF-κB, nuclear factor κB; TLR2, Toll-like receptor 2.
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Immunofluorescent staining
Cells were cultured on 4-chamber microscopeslides. After
IL-1β treatment, the cells were fixed in paraformaldehyde
solution (4%), incubated with mouse anti-p65 NF-κB
monoclonal antibodies for 1 h (Santa Cruz
Biotechnology, Inc.). Primary antibody was detected with
fluorescein isothiocyanate (FITC)-conjugated goat anti-
mouse IgG (Santa Cruz Biotechnology, Inc.). Samples
were viewed and photographed using a Zeiss Axiophot
microscope.
Statistical analysis
Data were analyzed using Student's t test or ANOVA and
Tukey's post hoc test. A value of p < 0.05 was considered
significant.
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